Autologous CAR-T Cell Manufacturing: Current Standing and Future Directions
A Look at What Drug Manufacturers are Likely Using to Make CAR-T Products
Supplement: MilliporeSigma Sees Opportunity in Continuous Processing
From the GEN Sounds of Science Podcast
Why CAR-T Therapies Don’t Work for Everyone Yet
Selecting the Best Type of T Cells for CAR-T May be Key to the Overall Efficacy of the Therapies
Cell-Centered: Scientists Embrace Cell-Replacement Therapy for Type 1 Diabetes
Forming Beta Cells from Stem Cells
For full access to this article login to GEN Select now.
Low-Volume Liquid Handling Gaining Favor
Novel Iteration Reduces Amount of Sample and Reagent Used and Speeds Processes
- In the unending quest to do more with less, the biotech industry has embraced low-volume liquid handling, and is continuing to advance the tools and techniques that make it a laboratory mainstay. With microtiter well volumes often in the nanoliter range, the benefits are obvious. Researchers use much less ...
Not registered yet? Please fill out the form below and enjoy complimentary access to this and an exclusive collection of premium content and personalization features as a GEN Select insider. Learn More.
Get GEN Select Access Now
- Do not put any letters or characters here if you are not a spy program.